Status:
COMPLETED
Dexmedetomidine Versus Propofol in Vitreoretinal Surgery
Lead Sponsor:
Rutgers, The State University of New Jersey
Conditions:
Retinal Detachment
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The investigators would like to determine if using Dexmedetomidine alone or in a reduced dose can prevent or reduce the incidence of adverse effects, while providing adequate sedation, and respiratory...
Detailed Description
Alpha2 adrenergic receptor agonist have been used increasingly as a new armamentarium to provide sedative/hypnotic, analgesic, anxiolytic and sympatholytic effects in the perioperative settings. Dexme...
Eligibility Criteria
Inclusion
- American Society of Anesthesiologists rating of I-III
- good renal and liver function
Exclusion
- renal and hepatic insufficiency
- uncontrolled diabetes
- uncontrolled hypertension
- severe cardiac disease Class III or IV
- heart blocks
- chronic use of sedatives, narcotics, alcohol or illicit drugs
- allergy to either propofol or dexmedetomidine
- pregnancy or inability to tolerate technique of the study drugs
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT01001429
Start Date
October 1 2009
End Date
November 1 2013
Last Update
August 21 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
UMDNJ-University Hospital
Newark, New Jersey, United States, 07102
2
University Hospital
Newark, New Jersey, United States, 07102